Targeting Focal Adhesion Kinase in Neuroblastoma

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 10, 2010, Pages 714-721

  Gillory, Lauren ^a   Beierle, Elizabeth A ^a  

^a Kentucky   (United States)

Author keywords

C4; Fak; Neuroblastoma; Nvp tae226; Y15

Indexed keywords

1,2,4,5 BENZENETETRAAMINE TETRAHYDROCHLORIDE; 2 [5 CHLORO 2 (2 METHOXY 4 MORPHOLINOANILINO) 4 PYRIMIDINYLAMINO] N METHYLBENZAMIDE; 6 [4 [3 (METHYLSULFONYLBENZYLAMINO) 5 (TRIFLUOROMETHYL)PYRIMIDIN 2 YLAMINO] 3,4 DIHYDROQUINOLIN 2(1H)ONE; ANTINEOPLASTIC AGENT; BENZALKONIUM CHLORIDE; CHLOROPYRAMINE; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; GSK 2256098; N METHYL N(3- [[2 (2 OXO 2,3 DIHYDRO 1H INDOL 5 YLAMINO) 5 TRIFLUOROMETHYL PYRIMIDIN 4 YLAMINO]METHYL]PYRIDIN 2 YL)METHANESULFONAMIDE; PF 04554878; PF 0562271; PF 573228; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 3; Y 15; [2 [5 CHLORO 2 [2 METHOXY 4 (4 MORPHOLINYL)PHENYLAMINO]PYRIMIDIN 4 YLAMINO]N METHYLBENZAMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER INVASION; CELL ADHESION; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; LYMPHANGIOGENESIS; MOLECULARLY TARGETED THERAPY; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING;

EID: 79952753908     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152010794728684     Document Type: Article

References (53)

1. Spix, C.; Pastore, G.; Sankila, R.; Stiller, C. A.; Steliarova-Foucher, E. Neuroblastoma incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. Eur. J. Cancer, 2006, 42 (13), 2081-2091.
2. Maris, J. M.; Matthay, K. K. Molecular biology of neuroblastoma. J. Clin. Oncol., 1999, 17 (7), 2264-2279.
3. Pearson, A. D.; Pinkerton, C. R.; Lewis, I. J.; Imeson, J.; Ellershaw, C.; Machin, D.; Group, E. N. S.; Group), C. s. C. a. L. G. C. f. U. K. C. s. C. S. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol., 2008, 9 (3), 247-256.
4. Stanton, L.; Schwab, M.; Bishop, J. Nucleotide sequence of the human N-myc gene. Proc. Natl. Acad. Sci. U. S. A., 1986, 83 (6), 1772-1786.
5. Brodeur, G.; Seeger, R.; Schwab, M.; Varmus, H.; Bishop, J. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science, 1984, 224 (4653), 1121-1124.
6. Schweigerer, L.; Breit, S.; Wenzel, A.; Tsunamoto, K.; Ludwig, R.; Schwab, M. Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. Cancer Res., 1990, 50 (14), 4411-4416.
7. Fredlund, E.; Ringnér, M.; Maris, J. M.; Påhlman, S. High Mycpathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc. Natl. Acad. Sci. U. S. A., 2008, 105 (37), 14094-14099.
8. Zaizen, Y.; Taniguchi, S.; Suita, S. The role of cellular motility in the invasion of human neuroblastoma cells with or without N-myc amplification and expression. J. Pediatr. Surg., 1998, 33 (12), 1765-1770.
9. Vasudevan, S. A.; Nuchtern, J. G.; Shohet, J. M. Gene profiling of high risk neuroblastoma. World J. Surg., 2005, 29 (3), 317-324.
10. Ma, L.; Young, J.; Prabhala, H.; Pan, E.; Mestdagh, P.; Muth, D.; Teruya-Feldstein, J.; Reinhardt, F.; Onder, T. T.; Valastyan, S.; Westermann, F.; Speleman, F.; Vandesompele, J.; Weinberg, R. A. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol., 2010, 12 (3), 247-256.
11. Terpe, H. J.; Christiansen, H.; Gonzalez, M.; Berthold, F.; Lampert, F. Differentiation and prognosis of neuroblastoma in correlation to the expression of CD44s. Eur. J. Cancer, 1995, 31A (4), 549-552.
12. Akeson, R.; Bernards, R. N-myc down regulates neural cell adhesion molecule expression in rat neuroblastoma. Mol. Cell. Biol., 1990, 10 (5), 2012-2016.
13. Korja, M.; Jokilammi, A.; Salmi, T. T.; Kalimo, H.; Pelliniemi, T. T.; Isola, J.; Rantala, I.; Haapasalo, H.; Finne, J. Absence of polysialylated NCAM is an unfavorable prognostic phenotype for advanced stage neuroblastoma. BMC Cancer, 2009, 9, 57.
14. Judware, R.; Culp, L. A. Over-expression of transfected N-myconcogene in human SKNSH neuroblastoma cells down-regulates expression of beta 1 integrin subunit. Oncogene, 1995, 11 (12), 2599-2607.
15. Judware, R.; Lechner, R.; Culp, L. A. Inverse expressions of the Nmyconcogene and beta 1 integrin in human neuroblastoma: relationships to disease progression in a nude mouse model system. Clin. Exp. Metastasis, 1995, 13 (2), 123-133.
16. Judware, R.; Culp, L. A. Concomitant down-regulation of expression of integrin subunits by N-myc in human neuroblastoma cells: differential regulation of alpha2, alpha3 and beta1. Oncogene, 1997, 14 (11), 1341-1350.
17. Bozzo, C.; Defilippi, P.; Silengo, L.; Tarone, G. Role of tyrosine phosphorylation in matrix-induced neurite outgrowth in human neuroblastoma cells. Exp. Cell. Res., 1994, 214 (1), 313-322.
18. Tanaka, N.; Fukuzawa, M. MYCN downregulates integrin alpha1 to promote invasion of human neuroblastoma cells. Int. J. Oncol., 2008, 33 (4), 815-821.
19. Gabarra-Niecko, V.; Schaller, M.; Dunty, J. FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev., 2003, 22 (4), 359-374.
20. Leventhal, P.; Shelden, E.; Kim, B.; Feldman, E. Tyrosine phosphorylation of paxillin and focal adhesion kinase during insulin-like growth factor-I-stimulated lamellipodial advance. J Biol. Chem., 1997, 272 (8), 5214-5218.
21. Kim, B.; Feldman, E. Insulin-like growth factor I prevents mannitol-induced degradation of focal adhesion kinase and Akt. J. Biol. Chem., 2002, 277 (30), 27393-27400.
22. Kim, B.; van Golen, C.; Feldman, E. Degradation and dephosphorylation of focal adhesion kinase during okadaic acidinduced apoptosis in human neuroblastoma cells. Neoplasia, 2003, 5 (5), 405-416.
23. Wu, L.; Bernard-Trifilo, J.; Lim, Y.; Lim, S.; Mitra, S.; Uryu, S.; Chen, M.; Pallen, C.; Cheung, N.; Mikolon, D.; Mielgo, A.; Stupack, D.; Schlaepfer, D. Distinct FAK-Src activation events promote alpha5beta1 and alpha4beta1 integrin-stimulated neuroblastoma cell motility. Oncogene, 2008, 27 (10), 1439-1448.
24. Cance, W.; Harris, J.; Iacocca, M.; Roche, E.; Yang, X.; Chang, J.; Simkins, S.; Xu, L. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin. Cancer Res., 2000, 6 (6), 2417-2423.
25. Lark, A.; Livasy, C.; Dressler, L.; Moore, D.; Millikan, R.; Geradts, J.; Iacocca, M.; Cowan, D.; Little, D.; Craven, R.; Cance, W. High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype. Mod. Pathol., 2005, 18 (10), 1289-1294.
26. Furuyama, K.; Doi, R.; Mori, T.; Toyoda, E.; Ito, D.; Kami, K.; Koizumi, M.; Kida, A.; Kawaguchi, Y.; Fujimoto, K. Clinical significance of focal adhesion kinase in resectable pancreatic cancer. World J. Surg., 2006, 30 (2), 219-226.
27. Judson, P.; He, X.; Cance, W.; Van Le, L. Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma. Cancer, 1999, 86 (8), 1551-1556.
28. Beierle, E.; Massoll, N.; Hartwich, J.; Kurenova, E.; Golubovskaya, V.; Cance, W.; McGrady, P.; London, W. Focal adhesion kinase expression in human neuroblastoma: immunohistochemical and real-time PCR analyses. Clin. Cancer Res., 2008, 14 (11), 3299-3305.
29. Beierle, E.; Trujillo, A.; Nagaram, A.; Kurenova, E.; Finch, R.; Ma, X.; Vella, J.; Cance, W.; Golubovskaya, V. N-MYC regulates focal adhesion kinase expression in human neuroblastoma. J. Biol. Chem., 2007, 282 (17), 12503-12516.
30. Lagodny, J.; Jüttner, E.; Kayser, G.; Niemeyer, C.; Rössler, J. Lymphangiogenesis and its regulation in human neuroblastoma. Biochem. Biophys. Res. Commun., 2007, 352 (2), 571-577.
31. van Iterson, V.; Leidenius, M.; von Smitten, K.; Bono, P.; Heikkilä, P. VEGF-D in association with VEGFR-3 promotes nodal metastasis in human invasive lobular breast cancer. Am. J. Clin. Pathol., 2007, 128 (5), 759-766.
32. Saintigny, P.; Kambouchner, M.; Ly, M.; Gomes, N.; Sainte-Catherine, O.; Vassy, R.; Czernichow, S.; Letoumelin, P.; Breau, J.; Bernaudin, J.; Kraemer, M. Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: concurrent expression in cancer cells from primary tumour and metastatic lymph node. Lung Cancer, 2007, 58 (2), 205-213.
33. Jennbacken, K.; Vallbo, C.; Wang, W.; Damber, J. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate, 2005, 65 (2), 110-116.
34. Beierle, E.; Dai, W.; Langham, M. J.; Copeland, E. r.; Chen, M. Expression of VEGF receptors in cocultured neuroblastoma cells. J. Surg. Res., 2004, 119 (1), 56-65.
35. Beierle, E.; Dai, W.; Langham, M. J.; Copeland, E. r.; Chen, M. VEGF receptors are differentially expressed by neuroblastoma cells in culture. J. Pediatr. Surg., 2003, 38 (3), 514-521.
36. Garces, C.; Kurenova, E.; Golubovskaya, V.; Cance, W. Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells. Cancer Res., 2006, 66 (3), 1446-1454.
37. Golubovskaya, V.; Beviglia, L.; Xu, L.; Earp, H. r.; Craven, R.; Cance, W. Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. J. Biol. Chem., 2002, 277 (41), 38978-38987.
38. Golubovskaya, V.; Zheng, M.; Zhang, L.; Li, J.; Cance, W. The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis. BMC Cancer, 2009, 9, 280.
39. Zheng, D.; Golubovskaya, V.; Kurenova, E.; Wood, C.; Massoll, N.; Ostrov, D.; Cance, W.; Hochwald, S. A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts. Mol. Carcinog., 2010, 49 (2), 200-209.
40. Xu, L.; Yang, X.; Bradham, C.; Brenner, D.; Baldwin, A. J.; Craven, R.; Cance, W. The focal adhesion kinase suppresses transformation-associated, anchorage-independent apoptosis in human breast cancer cells. Involvement of death receptor-related signaling pathways. J. Biol. Chem., 2000, 275 (39), 30597-30604.
41. Beierle, E.; Ma, X.; Trujillo, A.; Kurenova, E.; Cance, W.; Golubovskaya, V. Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines. Mol. Carcinog., 2010, 49 (3), 224-234.
42. Duxbury, M. S.; Ito, H.; Benoit, E.; Zinner, M. J.; Ashley, S. W.; Whang, E. E. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem. Biophys. Res. Commun., 2003, 311 (3), 786-792.
43. Shi, Q.; Hjelmeland, A. B.; Keir, S. T.; Song, L.; Wickman, S.; Jackson, D.; Ohmori, O.; Bigner, D. D.; Friedman, H. S.; Rich, J. N. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol. Carcinog., 2007, 46 (6), 488-496.
44. Wang, Z. G.; Fukazawa, T.; Nishikawa, T.; Watanabe, N.; Sakurama, K.; Motoki, T.; Takaoka, M.; Hatakeyama, S.; Omori, O.; Ohara, T.; Tanabe, S.; Fujiwara, Y.; Shirakawa, Y.; Yamatsuji, T.; Tanaka, N.; Naomoto, Y. TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells. Oncol. Rep., 2008, 20 (6), 1473-1477.
45. Halder, J.; Lin, Y. G.; Merritt, W. M.; Spannuth, W. A.; Nick, A. M.; Honda, T.; Kamat, A. A.; Han, L. Y.; Kim, T. J.; Lu, C.; Tari, A. M.; Bornmann, W.; Fernandez, A.; Lopez-Berestein, G.; Sood, A. K. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res., 2007, 67 (22), 10976-10983.
46. Beierle, E. A.; Trujillo, A.; Nagaram, A.; Golubovskaya, V. M.; Cance, W. G.; Kurenova, E. V., TAE226 inhibits human neuroblastoma cell survival. Cancer Invest., 2008, 26 (2), 145-151.
47. Golubovskaya, V.; Nyberg, C.; Zheng, M.; Kweh, F.; Magis, A.; Ostrov, D.; Cance, W., A small molecule inhibitor, 1,2,4,5- benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. J. Med. Chem., 2008, 51 (23), 7405-7416.
48. Hochwald, S.; Nyberg, C.; Zheng, M.; Zheng, D.; Wood, C.; Massoll, N.; Magis, A.; Ostrov, D.; Cance, W.; Golubovskaya, V. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle, 2009, 8 (15), 2435-2443.
49. Perry, B. C.; Wang, S.; Basson, M. D. Extracellular pressure stimulates adhesion of sarcoma cells via activation of focal adhesion kinase and Akt. Am. J. Surg., 2010, 200 (5), 610-614.
50. Beierle, E.; Ma, X.; Stewart, J.; Nyberg, C.; Trujillo, A.; Cance, W.; Golubovskaya, V. Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma. Cell Cycle, 2010, 9 (5), 1005-1015.
51. Kurenova, E.; Hunt, D.; He, D.; Magis, A.; Ostrov, D.; Cance, W. Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo. J. Med. Chem., 2009, 52 (15), 4716-4724.
52. Molckovsky, A.; Siu, L. L. First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J. Hematol. Oncol., 2008, 1, 20.
53. Schultze, A.; Fiedler, W. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert Opin. Investig. Drugs, 2010, 19 (6), 777-788.